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Background: Cancerous inhibitor of protein phosphatase 2A (CIP2A) is an oncoprotein that acts as a prognostic
marker for several human malignancies. In this study, we investigated the clinical significance of CIP2A and its
function in nasopharyngeal carcinoma (NPC).
Methods: Quantitative RT-PCR, western blot, and immunohistochemistry analyses were used to quantify CIP2A
expression in NPC cell lines and clinical samples. Kaplan-Meier curves were used to estimate the association between
CIP2A expression and patient survival. The functional role of CIP2A in NPC cell lines was evaluated by small interfering
RNA-mediated depletion of the protein followed by analyses of cell proliferation and xenograft growth.
Results: CIP2A levels were upregulated in NPC cell lines and clinical samples at both the mRNA and protein levels
(P < 0.01). Patients with high CIP2A expression had poorer overall survival (HR, 1.98; 95% CI, 1.16-3.34; P = 0.01) and
poorer disease-free survival (HR, 1.68; 95% CI, 1.07-2.62; P = 0.02) rates than patients with low CIP2A expression. In
addition, CIP2A expression status was an independent prognostic indicator for NPC patients. The depletion of CIP2A
expression inhibited c-Myc protein expression in NPC cell lines, suppressed cell viability, colony formation, and
anchorage-independent growth in vitro, and inhibited xenograft tumor growth in vivo.
Conclusions: Our data demonstrate that high CIP2A expression in patients was associated with poor survival in NPC,
and depletion of CIP2A expression inhibited NPC cell proliferation and tumor growth. Thus, these results warrant
further investigation of CIP2A as a novel therapeutic target for the treatment of NPC.
Keywords: Nasopharyngeal carcinoma, CIP2A, Proliferation, Cell growth, SurvivalIntroduction
Nasopharyngeal carcinoma (NPC) is an epithelial malig-
nancy of the nasopharynx, and global statistics obtained
for different world regions reveal that its distribution is
extremely unbalanced, with the highest incidence rates
occurring in Southern China [1,2]. According to data
from the International Agency for Research on Cancer,
there were an estimated 84,000 cases of NPC and 51,600* Correspondence: majun2@mail.sysu.edu.cn
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unless otherwise stated.NPC-related deaths in 2008 [3]. Although the increased
prevalence of intensity-modulated radiation therapy with
concurrent chemoradiation therapy has improved the
local and regional control of NPC for patients with
locoregionally advanced disease, their prognosis is still
poor due to recurrence and/or distant metastasis [4,5].
Thus, a better understanding of the underlying molecular
mechanisms involved in NPC pathogenesis and progres-
sion is essential for the development of novel therapeutic
strategies to treat patients with NPC.
Cancerous inhibitor of protein phosphatase 2A (CIP2A),
also known as KIAA1524 and p90, is a recently identified
human oncoprotein that inhibits the degradation of c-MYCThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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dephosphorylation of MYC at serine 62 [6-8]. In addition,
CIP2A and MYC appear to be regulated by a positive feed-
back loop that promotes the expression of both proteins
[7]. Originally identified as an oncoprotein, CIP2A contrib-
utes to the immortalization and malignant transformation
of human cells [6], and the depletion of CIP2A decreased
cell viability and anchorage-independent growth in a variety
of human malignancies [6-11]. More importantly, CIP2A
was recently found to be overexpressed at a high frequency
in most types of cancer and may serve as a prognostic
predictor [12-20]. However, the clinical significance and
biological function of CIP2A in NPC has not been thor-
oughly investigated to date.
In the present study, we examined both the mRNA
and protein expression levels of CIP2A in NPC cell lines
and tissue samples and further analyzed the clinical
significance of CIP2A in a cohort of NPC patients. In
addition, we explored the potential role of CIP2A in
NPC cell proliferation and tumor growth, which could
help to better understand the pathology of NPC and
may further provide a novel therapeutic target for the
treatment of NPC patients.
Results
Expression of CIP2A in NPC cells and tissues
Quantitative RT-PCR and western blot analyses were used
to determine the levels of CIP2A mRNA and protein in
NPC cell lines and the normal nasopharyngeal epithelial
cell line NP69. CIP2A was significantly upregulated in allFigure 1 Expression levels of CIP2A in NPC cell lines and clinical samp
NP69 and NPC cell lines. (C-D) Expression levels of CIP2A mRNA (C) and pr
GAPDH was used as the endogenous control. Data are presented as the msix NPC cell lines when compared to the NP69 cells at both
the mRNA and protein levels (Figure 1A-B). Furthermore,
we detected CIP2A mRNA expression in 18 freshly frozen
NPC tissues and 14 normal nasopharyngeal epithelial tis-
sues and found that CIP2A mRNA levels were considerably
higher in NPC tissues (Figure 1C). Similarly, CIP2A protein
was also increased in NPC tissues when compared to nor-
mal nasopharyngeal epithelial tissues (Figure 1D). These re-
sults suggest that CIP2A is upregulated in NPC.
CIP2A expression and the clinical variables of NPC patients
We then analyzed CIP2A protein expression levels in a set
of 280 paraffin-embedded NPC tissue samples using im-
munohistochemistry. Representative staining of CIP2A in
NPC tissue is shown in Figure 2A-H, and positive staining
of CIP2A was mainly observed in the cytoplasm. The pres-
ence of CIP2A protein was detected in 254 of the 280
(90.3%) cancer samples analyzed, and CIP2A protein ex-
pression was highly expressed in 184 of the 280 (65.7%)
NPC patients examined. Furthermore, patients with high
CIP2A expression exhibited a significant association with T
stage (P = 0.04), TNM stage (P < 0.01), distant metastasis
(P < 0.01), and patient death (P = 0.01). There were no sig-
nificant associations between CIP2A expression and pa-
tient age, sex, WHO type, VCA-IgA, EA-IgA, N stage, or
locoregional failure (Table 1).
CIP2A expression and survival of NPC patients
Kaplan-Meier analysis and the log-rank test were used to
calculate the effects of CIP2A on survival, and the resultsles. (A-B) Expression levels of CIP2A mRNA (A) and protein (B) in
otein (D) in NPC tissues and normal nasopharyngeal epithelial tissues.
ean ± SD, and P values were calculated with Student’s t-test.
Figure 2 Expression levels of CIP2A and survival of NPC patients. (A-H) Dicer1 protein expression is mainly localized to the cytoplasm.
(A, E) Negative staining (A: 200×; E: 400×); (B, F) Weak staining: light yellow (B: 200×; F: 400×); (C, G) Moderate staining: yellow brown (C: 200×;
G: 400×). (D, H) Strong staining: brown (D: 200×; H: 400×). (I-J) Patients with high CIP2A expression had poorer overall survival (I) and poorer
disease-free survival (J) rates than patients with low CIP2A expression.
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significantly associated with poorer overall and disease-free
survival rates than patients with low CIP2A expression (all
P < 0.01, Figure 2I-J). The cumulative 5-year survival rate
was 86.5% (95% CI, 79.7-93.3) in the low-CIP2A-expression
group, whereas it was only 74.5% (95% CI, 68.2-80.8) in the
high-CIP2A-expression group. CIP2A expression, TNM
stage, sex, age, WHO type, and EBV seromarkers were
analyzed using univariate and multivariate Cox regression
analyses. Univariate analyses indicated that patients with
high CIP2A expression and advanced disease stages exhib-
ited worse outcomes than those with low CIP2A expression
(Table 2). Multivariate analyses revealed that CIP2A expres-
sion and TNM stage were independent prognostic indica-
tors in NPC patients (all P < 0.05, Table 2).
Effects of CIP2A depletion on MYC expression and
cell proliferation
CIP2A protein expression was remarkably inhibited in
CNE-2 and SUNE-1 cells treated with siRNA specificallydirected against CIP2A when compared to those treated
with scrambled control siRNA (Figure 3A-B). More im-
portantly, depletion of CIP2A by siRNA suppressed the
MYC protein expression in both CNE-2 and SUNE-1
cells (Figure 3A-B). We also studied the effects of CIP2A
depletion on cell viability and proliferation ability using
MTT assays and colony formation assays. CNE-2 and
SUNE-1 cells transfected with siCIP2A displayed signifi-
cant growth inhibition compared to those transfected
with scrambled control siRNA (P < 0.05, Figure 3C).
Moreover, cells transfected with siCIP2A exhibited fewer
and smaller colonies compared to the controls (P < 0.05,
Figure 3D).
Effects of CIP2A depletion on tumor growth
The ability of cells to grow and form colonies on soft agar
is a hallmark characteristic of malignantly transformed
cells. To study the effects of CIP2A on the malignant
growth of NPC cells, we transfected siCIP2A or scrambled
control siRNA into CNE-2 and SUNE-1 cells and found
Table 1 Clinical characteristics of NPC patients according
to high and low CIP2A expression






≤45 130 48 (50) 82 (45) 0.39
>45 150 48 (50) 102 (55)
Sex
Male 208 72 (75) 136 (74) 0.84
Female 72 24 (25) 48 (26)
WHO type
I + II 10 2 (2) 8 (6) 0.50
III 270 94 (98) 176 (94)
VCA-IgA
< 1:80 41 16 (17) 25 (14) 0.49
≥ 1:80 239 80 (83) 159 (86)
EA-IgA
< 1:10 68 24 (25) 44 (24) 0.84
≥ 1:10 212 72 (75) 140 (76)
T Stage
T1-T2 137 55 (57) 82 (45) 0.04
T3-T4 143 41 (43) 102 (55)
N Stage
N0-N1 173 61 (64) 112 (61) 0.66
N2-N3 107 35 (36) 72 (39)
TNM Stage
I-II 86 40 (42) 46 (25) <0.01
III-IV 194 56 (58) 138 (75)
Locoregional failure
Yes 38 11 (11) 27 (15) 0.46
No 242 85 (89) 157 (85)
Distant metastasis
Yes 63 11 (11) 52 (28) <0.01
No 217 85 (89) 132 (72)
Death
Yes 67 14 (15) 53 (29) 0.01
No 213 82 (85) 131 (71)
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anchorage-independent growth of both CNE-2 and
SUNE-1 cells (all P < 0.05, Figure 3E). To further explore
whether CIP2A was required for NPC tumor growth
in vivo, we conducted xenograft tumor model assays by
subcutaneously injecting SUNE-1 cells stably expressing
shCIP2A or scrambled control siRNA into the dorsal flank
of several mice. CIP2A depletion resulted in a significant
reduction in tumor growth (P < 0.01, Figure 4A-B). Theaverage tumor weight was also significantly decreased in
the CIP2A depletion group compared to the scrambled
control siRNA-treated group (0.31 ± 0.11 g vs. 0.54 ±
0.24 g; P < 0.01, Figure 4C-D).
Discussion
In this study, CIP2A was upregulated in both NPC cell
lines and clinical samples, and those NPC patients with
high CIP2A expression exhibited the poorest survival
rates. Furthermore, silencing CIP2A expression influenced
MYC protein expression and further suppressed NPC cell
proliferation and tumor growth. Our results demonstrate
that the overexpression of CIP2A plays important roles in
the development and progression of NPC.
Reversible protein phosphorylation is one of the most
important biological mechanisms for signal transduction,
which is tightly regulated by protein kinases and phospha-
tases to maintain the balance of the protein’s phosphoryl-
ation status and control its biological functions. However,
there is considerable evidence indicating that the perturb-
ation of this balance, including the activation of protein
kinases and inhibition of phosphatases, contributes to the
origin and pathogenesis of several human diseases, includ-
ing cancer [21]. Protein phosphatase 2A (PP2A) is one
important type of serine/threonine phosphatase; PP2A is
inhibited in human cancers and functions as a tumor sup-
pressor. Furthermore, the inhibition of PP2A activity has
been found to result in the immortalization and malignant
transformation of human cells [22,23]. Interestingly,
CIP2A has recently been identified as an endogenous
PP2A inhibitor in human cancer cells using the tandem
affinity purification method. In addition, CIP2A inhibition
has been found to enhance the catalytic phosphatase
activity of the PP2A complex in several types of human
malignancies [6,24]. Furthermore, CIP2A also exhibits the
ability to transform human immortalized cells [6]; these re-
sults expand the general understanding of the mechanisms
that are critical for cancer development and progression.
CIP2A was previously demonstrated to be a human
oncoprotein due to its ability to transform human immor-
talized cells. Recently, CIP2A was found to be overex-
pressed at high frequencies in several types of human
cancers [6-11]. More importantly, several studies reported
that CIP2A could serve as a prognostic indicator for vari-
ous solid and hematological tumors, including non-small
cell lung cancer [12], colon cancer [13], breast cancer [14],
ovarian cancer [15], renal cancer [16], tongue cancer [17],
esophageal adenocarcinoma [18], bladder cancer [19], and
chronic myeloid leukemia [20]. In the present study,
CIP2A was significantly overexpressed in NPC cell lines
and clinical specimens at both the mRNA and protein
levels. Strikingly, NPC patients with high CIP2A protein
expression had poorer overall and disease-free survival
rates than those with low CIP2A protein expression.
Table 2 Univariate and multivariable Cox regression analyses of CIP2A expression levels and survival rates
Univariate analysis Multivariate analysis
Variable HR 95% CI P-value HR 95% CI P-value
Overall survival
CIP2A expression (High vs. Low) 2.13 1.18-3.84 0.012 1.85 1.02-3.35 0.042
TNM stage (III-IV vs. I-II) 3.16 1.57-6.39 0.001 2.87 1.42-5.82 0.003
Sex (Male vs. Female) 1.57 0.86-2.87 0.146
Age (>45 years vs. ≤45 years) 1.43 0.87-2.34 0.155
WHO type (III vs. I + II) 0.81 0.26-2.58 0.722
VCA-IgA (≥1:80 vs. < 1:80) 1.80 0.78-4.17 0.168
EA-IgA (≥1:10 vs. < 1:10) 1.19 0.66-2.15 0.555
Disease-free survival
CIP2A expression (High vs. Low) 1.92 1.16-3.17 0.011 1.70 1.03-2.82 0.039
TNM stage (III-IV vs. I-II) 2.87 1.59-5.17 <0.001 2.59 1.43-4.69 0.002
Sex (Male vs. Female) 1.57 0.93-2.68 0.094
Age (>45 years vs. ≤45 years) 1.25 0.82-1.93 0.301
WHO type (III vs. I + II) 0.78 0.29-2.12 0.622
VCA-IgA (≥1:80 vs. < 1:80) 2.06 0.95-4.46 0.068
EA-IgA (≥1:10 vs. < 1:10) 1.44 0.84-2.48 0.190
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low CIP2A protein expression was an independent prog-
nostic indicator in patients with NPC. These results sug-
gest that CIP2A expression status can serve as a valuable
prognostic biomarker to stratify NPC patients into differ-
ent risk groups and further guide individual therapy
choices for patients with NPC.
In addition to its biological significance in the promo-
tion of malignant transformation of human cells, CIP2A
also plays important roles in carcinogenesis and the pro-
gression of human cancers. Several recent studies have
reported that silencing CIP2A decreases cell viability
and suppresses anchorage-independent growth in several
types of human cancer cells [6-11]. It also promotes pro-
genitor cell self-renewal and protects cancer cells from
therapy-induced apoptosis or the induction of senes-
cence [25,26]. A recent study demonstrated that CIP2A
can regulate the cell cycle by targeting PLK1 [27]. More
importantly, recent studies have also demonstrated that
the depletion of CIP2A via siRNAs inhibits xenograft
tumor growth [6,9]. In our present study, we also
depleted CIP2A expression via siRNA to better under-
stand the function of CIP2A in NPC. Inhibition of
CIP2A expression significantly inhibited NPC cell viabil-
ity and proliferation in vitro. Furthermore, silencing
CIP2A suppressed xenograft tumor growth in vivo.
Taken together, these results demonstrate that the
dysregulation of CIP2A may contribute to the develop-
ment and progression of NPC.
In addition, the depletion of CIP2A expression via
siRNA suppressed MYC protein expression in NPC celllines. MYC is one of the most-studied oncogenes, and it is
involved in several malignant cellular processes. CIP2A
can inhibit the degradation of MYC and therefore enhance
its oncogenic activities by inhibiting the PP2A-mediated
dephosphorylation of MYC at serine 62 [6-8]. CIP2A and
MYC are regulated by a positive feedback loop that pro-
motes the expression of both proteins [7]. Furthermore,
the mechanisms of CIP2A activation and overexpression
in cancer cells has been investigated by several other
studies in which E2F1, ETS1, and ATF2 were found to
directly bind to the CIP2A promoter and further stimulate
CIP2A transcription [28-30]. Based on the functions and
mechanisms of CIP2A activation in human cancers, the
therapeutic targeting of CIP2A could facilitate a novel
strategy for cancer therapy, including the use of CIP2A
small RNA interference technology or the development of
small molecules that target the CIP2A-PP2A interaction
[6,31]. In addition, another alternative strategy to inhibit
CIP2A activity is to target the signaling mechanisms that
drive high CIP2A expression, such as the use of MYC [7],
EGFR [29], and MEK inhibitors [29].
Conclusions
In conclusion, the present study indicated that CIP2A over-
expression was associated with poor survival in patients
with NPC, and the depletion of CIP2A expression could in-
hibit cell viability and growth by promoting the stability of
the CIP2A protein. Our findings provide new insights into
the molecular mechanisms involved in the regulation of
NPC progression and provide novel therapeutic targets and
strategies for the treatment of NPC patients.
Figure 3 Effects of CIP2A depletion on MYC expression and NPC cell proliferation in vitro. (A-B) Effects of CIP2A siRNA on CIP2A and MYC
protein expression in CNE-2 and SUNE-1 cells detected by western blot analysis (A) and immunofluorescence staining (B); (C-E) Effects of CIP2A
siRNA on the cell viability (C), proliferation (D), and anchorage-independent growth (E) of CNE-2 and SUNE-1 cells. Data are presented as the
mean ± SD. *P < 0.05 compared to the control using Student’s t-test.
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Cell culture
Human NPC cell lines (CNE-1, CNE-2, SUNE-1, C666-1,
HNE1, and HONE1) were grown in RPMI-1640 (Invitro-
gen) medium supplemented with 10% fetal bovine serum
(Gibco). The immortalized nasopharyngeal epithelial cell
line NP69 was cultured in keratinocyte/serum-free medium
(Invitrogen) supplemented with bovine pituitary extract.
The 293FT cell line was maintained in DMEM (Invitrogen)
supplemented with 10% fetal bovine serum.
Clinical specimens
Eighteen freshly frozen NPC specimens and fourteen nor-
mal nasopharyngeal epithelium samples were obtained
from Sun Yat-sen University Cancer Center. In addition,
we collected 280 paraffin-embedded NPC specimens from
our hospital between January 2003 and February 2006.
None of the patients received any anti-tumor therapy
prior to the biopsy sample collection. The clinical featuresof all patients are provided in Table 1. TNM staging
was performed according to the 7th Edition of the
AJCC/UICC Cancer Staging Manual. All patients were
treated with conventional two-dimensional radiother-
apy, and patients with stage III-IV disease also received
platinum-based concurrent chemotherapy [32]. The
median follow-up time was 63.6 months (range: 5.2-
91.87). This study was approved by the Institutional
Ethical Review Board of Sun Yat-sen University Cancer
Center, and written informed consent was obtained
from each patient.
RNA extraction, reverse transcription, and quantitative PCR
Total RNA was isolated using TRIzol reagent (Invitrogen)
and reverse-transcribed using M-MLV reverse transcriptase
(Promega) and random primers (Promega). Quantitative
PCR reactions using a Platinum SYBR Green qPCR
SuperMix-UDG reagent (Invitrogen) were performed with
a Bio-Rad CFX96 sequence detection system (Bio-Rad
Figure 4 Effects of CIP2A depletion on NPC xenograft tumor growth in vivo. (A) SUNE-1 cells stably expressing shCIP2A or scrambled control
siRNA were subcutaneously injected into nude mice. SUNE-1 cells stably expressing shCIP2A had smaller tumors than scrambled controls after four weeks.
(B) The growth curves of tumor volumes. (C) Representative picture of xenograft tumors. (D) Tumor weight. Data are presented as the mean ± SD.
*P < 0.05 compared to the control using Student’s t-test.
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CIP2A: 5′-CCATATGCTCACTCAGATGATGT-3′ (for-
ward) and 5′-GTGTATCATCTCCACAGAGAGTT-3′ (re-
verse). Primers for GAPDH were as follows: 5′-CTC
CTCCTGTTCGACAGTCAGC-3′ (forward) and 5′-CCCA
ATACGACCAAATCCGTT −3′ (reverse). Reactions con-
taining either no template or no reverse transcriptase were
used as negative controls. GAPDH was used as the
normalization control, and the relative expression levels
were calculated by the 2-ΔΔCT method [33].Western blot analysis
Total protein was extracted with sample buffer
(62.5 mmol/L Tris–HCl, pH 6.8, 2% SDS, 10% glycerol,
and 5% 2-β-mercaptoethanol), and its concentration
was quantified using the Pierce® BCA Protein Assay Kit
(Thermo). Total protein was subsequently separated on
10% SDS-PAGE gels and transferred onto polyvinyli-
dene fluoride membranes (Millipore). The membranes
were blocked with 5% skim milk and incubated with
primary antibodies recognizing CIP2A (1:1,000; Abcam)
and MYC (1:5,000; Epitomics), followed by incubation
with anti-mouse or rabbit IgG secondary antibodies
(1:5,000; Sigma). Bands were detected by enhanced
chemiluminescence, and GAPDH levels (1:5,000; Epi-
tomics antibody) served as the loading control.Immunohistochemistry
Sections obtained from 280 paraffin-embedded NPC speci-
mens were tested for CIP2A expression by immunohisto-
chemical staining, as previously described [34,35]. Briefly,
samples were deparaffinized and rehydrated, and the
endogenous peroxidase activity was quenched. Antigen
retrieval was performed, and the sections were blocked
with bovine serum albumin and subsequently incubated
with an anti-CIP2A antibody (1:200; Abcam). Sections were
washed and subsequently incubated with a biotinylated
secondary antibody bound to a streptavidin-horseradish
peroxidase complex and visualized with 3,3-diaminobenzi-
dine. All sections were scored by two independent patholo-
gists, and the staining index was calculated as the product
of the staining intensity (1, no staining; 2, weak staining; 3,
moderate staining; 4, strong staining) and the proportion of
positive cells (1, <10%; 2, 10-35%; 3, 35-70%; 4, >70%).
Small interfering RNA transfection and the generation of
stably transfected cell lines
Double-stranded small interfering RNA targeting CIP2A
(50 nM, GenePharma; siCIP2A 1 5′-CUGUGGUUGUGU
UUGCACUTT-3′; siCIP2A 2 5′-ACCAUUGAUAUCCU
UAGAATT −3′) or scrambled control siRNA (5′-UAACA
AUGAGAGCACGGCTT-3′) were transfected into CNE2
and SUNE1 cell lines using Lipofectamine 2000 reagent
(Invitrogen). The CIP2A short hairpin RNA (shRNA) was
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plasmid using Bgl II and EcoR I enzymes (New England
Biolabs). The pSUPERretro-shCIP2A plasmid or empty
vector was co-transfected into 293FT cells along with the
retroviral packaging vector PIK. After transfection, the
supernatants were harvested and used to infect SUNE1
cells, and the stably transfected cells were selected with
puromycin and validated by western blot analysis.
Immunofluorescence staining
CNE-2 and SUNE-1 cells were grown on coverslips (Fisher
Scientific). After 24 h, cells were incubated with primary
antibodies against CIP2A (1:200; Abcam) and MYC (1:200;
Epitomics), and subsequently incubated with Alexa Fluor®
488 or 594 goat anti-mouse or anti-rabbit IgG antibodies
(Life Technologies). The coverslips were counterstained
with DAPI, and the images were captured using a confocal
laser-scanning microscope (Olympus FV1000).
MTT assay
CNE-2 and SUNE-1 cells were seeded in 96-well plates
at a density of 1,000 cells per well. At 1, 2, 3, 4, and
5 days, the cells were stained with 20 μl of MTT dye
(0.5 mg/ml, Sigma) for 4 h, after which the medium was
removed, and 100 μl of dimethyl sulfoxide (Sigma) was
added. The absorbance was measured at 490 nm with a
spectrophotometric plate reader.
Colony formation assay
CNE-2 and SUNE1 cells were seeded in six-well plates
at a density of 500 cells per well and cultured for 7 or
12 days. Colonies were fixed with 4% paraformaldehyde
solution, stained with 0.5% crystal violet, and counted
under an inverted microscope.
Anchorage-independent soft-agar growth
CNE-2 and SUNE-1 cells (2.5 × 104) were suspended in
1 ml of complete medium containing 0.66% agar (Sigma)
and then applied to the top of a 1% agar/complete
medium layer in six-well plates. Colonies were counted
under an inverted microscope after 9 or 12 days.
Xenograft tumor model
Three- to four-week-old male BALB/c nude mice were
purchased from the Medical Experimental Animal Center
of Guangdong Province (Guangzhou, China). All experi-
mental animal protocols were approved by the Animal
Care and Use Ethics Committee. SUNE-1 cells stably
expressing shCIP2A or scrambled control shRNA were
suspended in PBS, and 1 × 106 cells (100 μl) were subcuta-
neously injected into the dorsal flank of each mouse.
Tumors were examined every 3 days, and tumor volumes
were calculated. On day 28, the mice were sacrificed, and
the tumors were dissected and weighted.Statistical analysis
Data are presented as the mean ± SD, and differences
between groups were analyzed using Student’s t-test or a
chi-squared test. Receiver operation characteristic (ROC)
curves were used to determine the optimal cutoff values
for low and high CIP2A expression. The Kaplan-Meier
method and log-rank test were used to estimate survival
rates, and hazard ratios (HRs) were calculated using un-
adjusted univariate Cox regression analysis. Multivariate
Cox regression analysis was used to test for independent
prognostic factors. All statistical analyses were performed
with SPSS 16.0 software, and P values of < 0.05 were con-
sidered statistically significant.
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